Acrivon Therapeutics (ACRV) Competitors $1.55 -0.09 (-5.49%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$1.54 -0.02 (-0.97%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. TERN, ACB, SLDB, ATXS, SLRN, CDTX, HUMA, DRUG, LFCR, and ALMSShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Acelyrin (SLRN), Cidara Therapeutics (CDTX), Humacyte (HUMA), Bright Minds Biosciences (DRUG), Lifecore Biomedical (LFCR), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Terns Pharmaceuticals Aurora Cannabis Solid Biosciences Astria Therapeutics Acelyrin Cidara Therapeutics Humacyte Bright Minds Biosciences Lifecore Biomedical Alumis Acrivon Therapeutics (NASDAQ:ACRV) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk. Is ACRV or TERN more profitable? Terns Pharmaceuticals' return on equity of -32.76% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -47.95% -43.73% Terns Pharmaceuticals N/A -32.76%-31.33% Do analysts prefer ACRV or TERN? Acrivon Therapeutics presently has a consensus price target of $21.80, indicating a potential upside of 1,306.45%. Terns Pharmaceuticals has a consensus price target of $18.38, indicating a potential upside of 525.00%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Acrivon Therapeutics is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer ACRV or TERN? In the previous week, Terns Pharmaceuticals had 2 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 7 mentions for Terns Pharmaceuticals and 5 mentions for Acrivon Therapeutics. Terns Pharmaceuticals' average media sentiment score of 1.14 beat Acrivon Therapeutics' score of 0.69 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Terns Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ACRV or TERN? Acrivon Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500. Does the MarketBeat Community believe in ACRV or TERN? Terns Pharmaceuticals received 6 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 97.37% of users gave Acrivon Therapeutics an outperform vote while only 59.72% of users gave Terns Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAcrivon TherapeuticsOutperform Votes3797.37% Underperform Votes12.63%Terns PharmaceuticalsOutperform Votes4359.72% Underperform Votes2940.28% Do institutionals & insiders believe in ACRV or TERN? 71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 15.1% of Terns Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings & valuation, ACRV or TERN? Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$60.39M-$2.44-0.64Terns PharmaceuticalsN/AN/A-$90.21M-$1.13-2.60 SummaryTerns Pharmaceuticals beats Acrivon Therapeutics on 8 of the 15 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.59M$6.72B$5.45B$7.79BDividend YieldN/A3.11%5.11%4.23%P/E Ratio-0.577.2722.2818.46Price / SalesN/A241.43398.76104.20Price / CashN/A65.8538.1834.62Price / Book0.296.356.714.21Net Income-$60.39M$143.17M$3.22B$248.18M7 Day Performance-23.65%4.58%4.14%4.70%1 Month Performance-30.80%-1.39%-0.89%1.41%1 Year Performance-84.50%-2.64%16.75%3.96% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics3.2342 of 5 stars$1.55-5.5%$21.80+1,306.5%-81.7%$48.59MN/A-0.5758Short Interest ↓Gap UpHigh Trading VolumeTERNTerns Pharmaceuticals4.2239 of 5 stars$2.71+12.9%$18.38+578.0%-40.1%$236.58MN/A-2.3040Positive NewsACBAurora Cannabis0.519 of 5 stars$4.20-5.4%N/A-30.1%$236.10M$320.81M84.021,340SLDBSolid Biosciences4.0122 of 5 stars$3.03+18.8%$15.67+417.1%-64.0%$234.80M$8.09M-1.00100Positive NewsHigh Trading VolumeATXSAstria Therapeutics1.843 of 5 stars$4.11+1.7%$26.60+547.2%-44.9%$231.94MN/A-1.9730Positive NewsSLRNAcelyrin2.8098 of 5 stars$2.28+3.6%$9.60+321.1%-48.6%$230.07MN/A-0.93135News CoveragePositive NewsCDTXCidara Therapeutics4.3274 of 5 stars$20.68+6.4%$39.14+89.3%+66.5%$226.51M$1.28M-0.8190Positive NewsHUMAHumacyte2.6525 of 5 stars$1.45-13.7%$13.71+845.8%-63.4%$224.92M$1.57M-1.08150Positive NewsGap DownDRUGBright Minds Biosciences3.5085 of 5 stars$31.89-3.7%$84.33+164.5%+2,825.5%$224.63MN/A-187.58N/ANews CoveragePositive NewsLFCRLifecore Biomedical1.4911 of 5 stars$6.04-5.8%$8.00+32.5%-2.2%$223.63M$130.86M-10.79690ALMSAlumis2.489 of 5 stars$4.70-6.0%$26.00+453.2%N/A$221.94MN/A0.00N/A Related Companies and Tools Related Companies Terns Pharmaceuticals Competitors Aurora Cannabis Competitors Solid Biosciences Competitors Astria Therapeutics Competitors Acelyrin Competitors Cidara Therapeutics Competitors Humacyte Competitors Bright Minds Biosciences Competitors Lifecore Biomedical Competitors Alumis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRV Stock Free ACRV Stock Alerts